# PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

Source: https://onco.cc/trials/nct07028424/  
OnCo record `nct07028424` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of liposomal irinotecan, paclitaxel / nab-paclitaxel, gemcitabine, cAPOX (capecitabine, oxaliplatin) and other drugs in pancreatic cancer, run by GERCOR - Multidisciplinary Oncology Cooperative Group, not yet recruiting.

## Summary

PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment is a phase 2, randomised interventional study registered as NCT07028424 by GERCOR - Multidisciplinary Oncology Cooperative Group, with a registry enrolment figure of 206 participants, started 2025-07 and due to reach its primary completion in 2029-07. Interventions recorded: Nal-IRI; Ciprofloxacin; Paclitaxel; Gemcitabine; Oxaliplatin; Leucovorin; 5-Fluorouracil; Placebo. Conditions listed: PDAC - Pancreatic Ductal Adenocarcinoma. Primary outcome: 6-month progression-free survival (PFS) rate post randomization Step 1 (R1) in Arm 1A. Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: PANORAMIX
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07028424
- Phase: 2
- Setting: Pancreatic Cancer First-line NALIRIFOX Optimization With 5-FU Maintenance and Role of Antibiotics and Microbiota Exploration in Second-line Treatment - A Non-comparative, Randomized Phase II PANORAMIX GERCOR G-116 PRODIGE 105 Study.
- Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
- Enrolled: 206

## Sources

- ClinicalTrials.gov NCT07028424: https://clinicaltrials.gov/study/NCT07028424

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Liposomal irinotecan](https://onco.cc/drugs/liposomal-irinotecan/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07028424.json